Evidence map›Paper›PMID 35295263›Full record

ArticleFrontiers in cardiovascular medicine2022

Real-World Experience With a Large Bore Vascular Closure Device During TAVI Procedure: Features and Predictors of Access-Site Vascular Complications.

Giulia Masiero, Livio D'Angelo, Luca Nai Fovino, Tommaso Fabris, Francesco Cardaioli, Giulio Rodinò, Alice Benedetti, Mauro Boiago, Saverio Continisio, Carolina Montonati and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Giulia MasieroDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Livio D'AngeloDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Luca Nai FovinoDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Tommaso FabrisDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Francesco CardaioliDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Giulio RodinòDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Alice BenedettiDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Mauro BoiagoDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Saverio ContinisioDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Carolina MontonatiDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Tommaso SciarrettaDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Vittorio ZuccarelliDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Andrea ScottiDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Giulia LorenzoniDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Andrea PaveiDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Massimo NapodanoDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Chiara FraccaroDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Sabino IlicetoDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Alfredo MarcheseUnit of Cardiology, GVM Care and Research, Anthea Hospital, Bari, Italy.
Giovanni EspositoDivisions of Cardiology and Cardiothoracic Surgery, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
Giuseppe TarantiniDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Backgrounds: Among vascular closure devices (VCDs), the novel collagen plug-based MANTA VCD is the first designed for large bore percutaneous access. We aimed to assess the features and predictors of access-site vascular complications in an unselected trans-femoral transcatheter aortic valve replacement (TF-TAVR) population. Methods: Patients undergoing large bore arteriotomy closure with 18F MANTA VCD following TF-TAVR at a large tertiary care center from September 2019 to January 2021 were prospectively analyzed. Primary Outcome was the MANTA VCD access-site-related complications according to Valve Academic Research Consortium-3 (VARC) definitions. Its incidence and predictors were evaluated. Results: Eighty-eight patients (median age 82 years, 48% male, 3.3 median Society of Thoracic Surgeons score) undergoing TF-TAVR were included, mostly (63%) treated with a self-expandable device and with outer diameter sizes varied from 18F to 24-F. MANTA VCD technical success rate was 98%, while 10 patients (11%) experienced MANTA VCD access-site vascular complications which included 8% of minor complications and only to 2% of major events resulting in VARC type ≥2 bleeding. Vessel occlusion/stenosis (60%), perforation (20%), and pseudoaneurysm/dissection/hematoma (20%) occurred, but all were managed without surgical treatment. Independent predictors of failure were age ( Conclusions: In a more comers TF-TAVR population, MANTA VCD was associated with reassuring rates of technical success and major access-site vascular complications. Avoiding lower vessel size and less puncture site distance to CFA bifurcation might further improve outcomes.

Indexed as

common femoral artery (CFA)multidetector computed tomography (MDCT)transfemoral transcatheter aortic valve implantation (TF-TAVI)valve academic research consortium (VARC)vascular closure device (VCD)vascular complications

Identifiers

PMID35295263
PMCPMC8919188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.